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Abstract
Ergosterol is an important constituent of fungal membranes. Azoles inhibit ergosterol biosynthesis, although the cellular
basis for their antifungal activity is not understood. We used multiple approaches to demonstrate a critical requirement for
ergosterol in vacuolar H+-ATPase function, which is known to be essential for fungal virulence. Ergosterol biosynthesis
mutants of S. cerevisiae failed to acidify the vacuole and exhibited multiple vma2 phenotypes. Extraction of ergosterol from
vacuolar membranes also inactivated V-ATPase without disrupting membrane association of its subdomains. In both S.
cerevisiae and the fungal pathogen C. albicans, fluconazole impaired vacuolar acidification, whereas concomitant ergosterol
feeding restored V-ATPase function and cell growth. Furthermore, fluconazole exacerbated cytosolic Ca2+ and H+ surges
triggered by the antimicrobial agent amiodarone, and impaired Ca2+ sequestration in purified vacuolar vesicles. These
findings provide a mechanistic basis for the synergy between azoles and amiodarone observed in vitro. Moreover, we show
the clinical potential of this synergy in treatment of systemic fungal infections using a murine model of Candidiasis. In
summary, we demonstrate a new regulatory component in fungal V-ATPase function, a novel role for ergosterol in vacuolar
ion homeostasis, a plausible cellular mechanism for azole toxicity in fungi, and preliminary in vivo evidence for synergism
between two antifungal agents. New insights into the cellular basis of azole toxicity in fungi may broaden therapeutic
regimens for patient populations afflicted with systemic fungal infections.
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Introduction
Pathogenic fungal species, including Aspergillus, Candida, Histo-
plasma and Cryptococcus among others, cause infections ranging
from mucocutaneous disorders to life-threatening invasive diseases
that can involve any organ. In the past two decades, expanding
populations of immunocompromised patients and increased use of
invasive devices and implants have led to an increase in the
incidence of fungal infections [1,2]. Currently, four major
categories of antifungal therapeutics are available to treat invasive
fungal infections: polyenes, azoles, echinocandins and flucytosine
[3]. Azole drugs are the most widely deployed in clinics, and
inhibit the biosynthesis of ergosterol, the fungal-specific sterol. The
primary molecular target of azole drugs is Erg11p (Entrez
GeneID: 856398), a P450 cytochrome that catalyzes 14a-
demethylation of lanosterol in the ergosterol biosynthesis pathway
[4]. Besides azoles, a number of other drugs such as allylamines
and morpholines used in medicine and agriculture also inhibit
ergosterol biosynthesis [5,6].
Ergosterol is an important constituent of membrane lipids,
similar to vertebrate cholesterol, and modulates the fluidity,
permeability and thickness of the membrane. These sterols
preferentially associate with sphingolipids in microdomains that
have been postulated to have important roles in membrane
organization and function [7,8]. Ergosterol is most abundant in
the plasma membrane and has been implicated in several cellular
processes including sporulation, pheromone signaling and plasma
membrane fusion during mating and endocytosis [9,10]. Discern-
able amounts of ergosterol have also been found in membranes of
intracellular organelles including peroxisomes, mitochondria,
vacuoles and ER [11]. Some studies have ascribed a regulatory
role at these intracellular compartments, including homotypic
vacuole fusion [12], mitochondrial biogenesis and inheritance, and
protein sorting along exocytosis and endocytosis pathways [13,14].
The absence of ergosterol in mammals and suppression of fungal
proliferation by a battery of ergosterol biosynthesis inhibitors
emphasize the importance and utility of ergosterol as an effective
target in antifungal chemotherapy. Yet, despite nearly two decades
of use and the general recognition of the importance of ergosterol
to fungal cells our understanding of the specific cellular processes
disrupted by ergosterol deprivation following azole therapy
remains minimal.
The limited categories of antifungal agents and emergence of
resistance to existing antimycotics have prompted a search for
compounds with alternative modes of action. The anti-arrhythmia
drug, amiodarone, was recently documented to exhibit fungicidal
activity [15,16]. This cationic amphipathic compound inserts into
the lipid bilayer where it elicits membrane hyperpolarization, and
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influx of H+ and Ca2+ into the cytoplasm [15,17]. Within minutes,
amiodarone also elicits a transcriptional response to starvation and
blocks cell cycle progression [18]. A screen of the yeast haploid
deletion library for amiodarone hypersensitivity revealed multiple
vma genes encoding subunits of the vacuolar membrane H+-
ATPase [15]. The V-ATPase is critical for generation of a pH
gradient that drives secondary transporters to maintain cellular ion
homeostasis. Since the fungicidal activity of amiodarone appears
to be tightly coupled to ion stress [19], hypersensitivity of vma
mutants was ascribed to defects in ion homeostasis. Notably,
deletion mutants of several erg genes in the ergosterol biosynthesis
pathway were also identified in the screen [15], although the
underlying mechanism for their amiodarone hypersensitive
phenotype was unclear. Meanwhile, a screen of the yeast haploid
deletion mutant library for strains with alterations in vacuolar pH
revealed that erg mutants, like vma mutants, had severely alkaline
vacuoles (Brett, C.L., Rao. R. et al., unpublished data). A separate
study showed that sphingolipid, the other major membrane lipid
component found associated with ergosterol in detergent-resistant
microdomains, was required for the structural integrity of V-
ATPase domains [20]. In light of these observations, we
investigated a potential link between ergosterol and V-ATPase
function, which led to a mechanistic basis for the antifungal
activity of azole drugs. As a first step in exploiting our observations
for improved management of invasive fungal diseases, we assessed
the efficacy of combining fluconazole with ion homeostasis-
disruptive agent amiodarone in a murine Candidiasis model.
Results
Mutants defective in ergosterol biogenesis exhibit
multiple vma2 phenotypes
A genome-wide screen of the S. cerevisiae haploid deletion
collection for hypersensitivity to the antifungal agent amiodarone
revealed multiple vma and erg mutants [15]. Given our previous
observation that amiodarone triggered Ca2+ and H+ influx leading
to fungal death from ion stress [15,19] and the importance of V-
ATPase in ion homeostasis, we considered the possibility that
ergosterol may be important for V-ATPase function. A systematic
examination of viable erg null mutants (erg2D [Entrez GeneID:
855242], erg3D [Entrez GeneID: 850745], erg6D [Entrez GeneID:
855003] and erg24D [Entrez GeneID: 855441]) revealed multiple
vma2 phenotypes, with erg24D displaying the most severe defects.
In addition to hypersensitivity to amiodarone (Fig. 1A), erg24D was
unable to grow at alkaline pH (Fig. 1B), a defining phenotype of
vma mutants indicative of the inability to acidify vacuoles.
Furthermore, erg24D exhibited hypersensitivity to Zn2+ toxicity
and to the calcineurin inhibitor FK506, consistent with broad ion
homeostasis defects characteristic of vma mutants (Fig. 1C–D).
Yeast strains defective in trafficking of chitin synthase, including
vma mutants, are more sensitive to toxicity from calcofluor white,
an antimicrobial agent that binds to cell wall chitin. We showed
that erg24D shared calcofluor white hypersensitivity with vma2D
(Fig. 1E). Poor growth of vma mutants on high concentrations of
non-fermentable carbon sources has been ascribed to oxidative
stress from respiration. Although erg24D was able to grow on non-
fermentable carbon sources, growth was significantly impaired
(Fig. 1F). Overall, the novel observation that ergosterol biogenesis
mutants largely phenocopy vma mutants suggests that cellular
ergosterol content may be important for the function of V-
ATPase.
Ergosterol is critical for V-ATPase function
V-ATPase hydrolyzes ATP and acidifies vacuolar compart-
ments. To assess a possible requirement for ergosterol in V-
ATPase function, we first measured the vacuolar pH in erg mutants
using the pH-sensitive fluorescent dye BCECF. The acetoxy
methyl ester of BCECF is taken up by cells and de-esterified in the
vacuole where it accumulates [21]. While the vacuolar pH of wild-
type cells was 6.0, vacuoles of vma2D (Entrez GeneID: 852424)
cells were significantly more alkaline, around pH 7, as would be
expected for loss of proton pump capacity (Fig. 2A). Vacuolar pH
of all viable erg mutants closely resembled that of the vma mutant,
as shown for erg24D (Fig. 2A). Next, we purified intact vacuolar
vesicles from wild type, erg24D and vma2D strains, and compared
V-ATPase function, including rates of proton pumping and ATP
hydrolysis. There was no V-ATPase activity detectable in vma2D
vacuoles as expected, whereas in vitro ATPase and H+ pumping
activity were both diminished to about 40% of wild type levels in
erg24D (Fig. 2B). Examination of sterol profiles in purified vacuoles
confirmed the presence of ergosterol in wild type vacuoles and its
absence in erg24D (not shown). Taken together, these results
provide evidence for a role for ergosterol in V-ATPase activity.
The P-type H+-ATPase Pma1 (Entrez GeneID: 852876) has
been documented to associate with ergosterol enriched domains
[22,23]. Upon glucose activation, it pumps protons out of cells to
acidify the extracellular medium. To assess the effect of ergosterol
depletion on Pma1 function, we examined extracellular acidifica-
tion upon glucose activation in erg24D cells. As shown in Fig. 2C,
the kinetics of medium acidification was substantially similar
between the wild type and erg24D, while a previously characterized
PMA1 mutant, pma1-105, reported to have a 65% reduction in
activity, exhibited slower acidification rate as expected [24]. These
data suggest that ergosterol is not required for Pma1 function and
support the specificity of the ergosterol effect on V-ATPase.
To investigate the mechanism underlying the requirement of
ergosterol for optimal V-ATPase function, we first asked if V-
ATPase localization was altered in the erg24D mutant. The V-
ATPase is made up of 14 subunits organized into the Vo sector,
integral to the membrane, and the cytoplasmic V1 sector that
reversibly dissociates from the membrane [25]. Figure 3A & 3B
show that representative subunits from the Vo sector (Vph1-GFP)
and the V1 sector (Vma5-GFP) colocalized with the vacuolar
membrane stain (FM4-64) in erg24D cells, similar to the isogenic
wild type. It was possible that the ergosterol biogenesis defect
Author Summary
Systemic fungal infections impose a significant threat to
public health and therapeutic options to treat these
diseases remain limited. Azoles represent the largest
category of anti-fungal drugs and repress fungal growth
by inhibiting biosynthesis of ergosterol, an important
constituent of fungal membranes. Despite the wide use of
azoles in the clinic for decades, the cellular basis for their
antifungal mechanism remains elusive. In this study, we
use a range of genetic, cellular and biochemical approach-
es to reveal a requirement for ergosterol in vacuolar H+-
ATPase function. V-ATPase plays essential roles in diverse
cellular processes, and is required for fungal virulence.
Concomitant ergosterol feeding restores vacuolar acidifi-
cation and growth in cells treated with fluconazole. These
results suggest that the critical requirement for ergosterol
in V-ATPase function may underlie the antifungal activity
of azoles. Moreover, we show in a mouse Candidiasis
model that combining an ion homeostasis-disruptive drug
with azole is an effective approach to treat fungal
infections.
Azoles Disrupt Fungal V-ATPase Function
PLoS Pathogens | www.plospathogens.org 2 June 2010 | Volume 6 | Issue 6 | e1000939
Azoles Disrupt Fungal V-ATPase Function
PLoS Pathogens | www.plospathogens.org 3 June 2010 | Volume 6 | Issue 6 | e1000939
significantly decreased V-ATPase expression or caused the
dissociation of V1 from Vo domain. However, analyses of
representative V-ATPase subunits in vacuolar vesicles purified
from the wild type and erg24D showed similar expression levels
and V1/Vo ratios that were identical between the two strains
(Fig. 3C & 3D).
The oligosaccharide Methyl-b-Cyclodextrin (MbCD) extracts
sterols from cellular membranes. We observed a dose dependent
loss of V-ATPase activity following treatment of purified vacuolar
vesicles with MbCD, which could be blocked by preloading
cholesterol into MbCD (Fig. 4A). Both ATP hydrolysis rates and
H+ pumping declined at similar rates, suggesting an inhibition of
the intact V1Vo complex. This was verified by immunoblot
analysis of vacuolar membranes collected by centrifugation after
MbCD treatment (Fig. 4B): we did not observe a loss of either V1
(Vma2p) or Vo (Vph1p) subunits, suggesting that the two sectors
remain associated after ergosterol extraction. In contrast, a
previous study pointed to a role for sphingolipids in maintaining
structural integrity of the V-ATPase enzyme complex [20]. We
conclude that ergosterol constitutes a critical component in the
lipid membrane environment for V-ATPase function.
The antifungal drug fluconazole disrupts V-ATPase
function
Azole drugs exert their fungistatic effect by inhibiting ergosterol
biosynthesis, specifically targeting lanosterol demethylase (Erg11p),
which is the enzymatic step immediately upstream from Erg24p.
Despite the wide spread use of azole antifungals, our understand-
ing of the specific cellular pathways disrupted by azoles is limited.
In addition to ergosterol depletion, fluconazole treatment results in
accumulation of lanosterol (substrate of Erg11p) and its derivative
14-methyl-3,6 diol [26]. Based on analysis of sterol profiles in
fluconazole susceptible and resistant strains, it was concluded that
14-methyl-3,6 diol toxicity [26,27] was responsible for azole-
mediated growth arrest. To specifically assess the functional effect
of ergosterol depletion following azole treatment, we used the S.
cerevisiae strain WPY361 with a gain-of-function mutation in UPC2
(Entrez GeneID: 851799), upc2-1, that allows overexpression of
ATP-binding cassette transporters required for uptake of exoge-
nously added sterol under aerobic condition [28,29]. Table 1
shows that growth inhibition caused by fluconazole treatment in
WPY361 can be reversed by exogenous supply of ergosterol. To
examine whether ergosterol feeding represses endogenous sterol
metabolism and reduces accumulation of intermediates and
derivatives, we analyzed sterol profiles in upc2-1 cells after six
hours of exposure to fluconazole and exogenous ergosterol. As
expected, fluconazole alone caused reduction of ergosterol content
(nine-fold) and accumulation of lanosterol and a major derivative,
likely to be 14-methyl 3,6-diol (Fig. S1). Compared with cells
treated with fluconazole alone, cells treated with fluconazole and
ergosterol had three-fold higher ergosterol content, yet the level of
lanosterol and its derivatives remained the same (Fig. S1). These
data indicate that ergosterol feeding did not reduce accumulation
of intermediates and derivatives. Thus, depletion of ergosterol,
rather than the toxicity of intermediates and derivatives, is a
plausible mechanism for the antifungal activity of fluconazole.
Based on our evidence that ergosterol was required for optimal
V-ATPase function, we predicted that azole treatment would
similarly impair activity of the V-ATPase. Indeed, we show that
fluconazole treatment resulted in a dose-dependent alkalinization
of vacuolar pH, consistent with depletion of ergosterol from the
vacuolar membrane (Fig. 5A). Furthermore, vacuolar membrane
vesicles purified from fluconazole treated cells showed significant
reductions in both H+ pumping rates and ATPase activity (Fig. 5B).
Next, we evaluated the effect of ergosterol feeding on vacuolar pH
in the upc2-1 mutant. Not only did exogenous ergosterol restore
growth in fluconazole treated cells, vacuolar acidification closely
resembled that of untreated cells (Fig. 5C & 5D). This correlation
strengthens the hypothesis that V-ATPase inhibition contributes to
the cellular mechanism of azole activity.
Figure 1. erg24D exhibits multiple vma2 phenotypes. Growth of WT, vma2D, erg24D strains under different conditions. Values were normalized
to growth of each strain under control condition (A and C), to growth of each strain at pH 4.3 (B), to growth of each strain at pH 6 without FK506 (D),
or to growth of WT under the two conditions with non-fermentable carbon source (F). (E) Growth of the strains in YPD or YPD supplemented with
Calcofluor white. All measurements were in triplicate, and means and standard deviations are plotted. p values of two-tailed t-test are shown.
doi:10.1371/journal.ppat.1000939.g001
Figure 2. ERG24 deletion impairs the function of V-ATPase but not Pma1p. (A) Vacuolar pH of WT, erg24D and vma2D strains measured
with pH sensitive fluorophore BCECF-AM, which accumulates in the yeast vacuole. (B) Initial H+ pumping rate was calculated from DA490–540 during
the first 60 s after initiating the reaction. ATPase activity was calculated from drop of A340 between 3 and 6 minutes after initiating the reaction.
Means and standard deviations are plotted from data for at least three independent vacuolar vesicle preparations. p values of two-tailed t-test are
shown. (C) Medium acidification by Pma1 upon glucose activation was measured as described in Methods. Extracellular pH (pHout) was recorded after
glucose was added to 2% at time 0.
doi:10.1371/journal.ppat.1000939.g002
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Figure 4. Ergosterol is critical for V-ATPase function. (A) WT vacuolar vesicles were incubated with MbCD or MbCD preloaded with cholesterol
(cholesterol to MbCD ratio 1:20 by weight) at 4uC for 30 min. Vacuolar vesicles were spun down and analyzed for ATPase function. (B) WT vacuolar
vesicles treated with MbCD for 30 min at 4uC were spun down and used for immunoblotting to assess the abundance of Vph1p and Vma2p.
doi:10.1371/journal.ppat.1000939.g004
Figure 3. Expression and localization of V-ATPase in erg24D. Vph1p (A) and Vma5p (B) were tagged with C-terminal GFP at their
chromosomal loci in WT and erg24D strains. Vacuolar membranes were stained with FM4-64 for 30 min in YPD and chased for another 30 min with
fresh YPD. (C) Immunoblotting of Vph1p and Vma2p in vacuolar vesicles isolated from WT and erg24D. (D) Vma2p to Vph1p ratio in WT was
designated as V1/Vo ratio of 1. Calculation was based on data from three independent vacuolar vesicle preparations for each strain. Means of the
ratios and standard deviation are plotted.
doi:10.1371/journal.ppat.1000939.g003
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To extend these observations in the human pathogen Candida
albicans, we monitored vacuolar uptake of the fluorescent weak
base quinacrine. Previous studies have demonstrated pH-depen-
dent vacuolar accumulation of quinacrine, which was abolished in
the homozygous vma72/2 mutant [30]. We observed robust
quinacrine fluorescence in C. albicans vacuoles, colocalizing with
FM4-64 staining of vacuolar membranes. Fluconazole treatment
drastically reduced vacuolar accumulation of quinacrine in most
cells, indicative of impaired vacuolar acidification (Fig. 5E).
Additionally, trafficking of FM4-64 to the vacuolar membrane
was impaired, consistent with endocytosis defects seen in vma
mutants [30]. We note that following 6 h of fluconazole treatment,
cells failed to divide but continue to increase in size, as previously
reported [9]. These data suggest that the requirement of ergosterol
for V-ATPase function is conserved in fungi. Given the
importance of V-ATPase function and vacuolar acidification in
diverse cellular processes, we conclude that disruption of V-
ATPase function plays a critical role in antifungal activity of azole
drugs. Consistent with this conclusion, both vma72/2 and erg242/2
mutants of C. albicans exhibit defective virulence in murine models of
Candidiasis [30,31].
Impairment of V-ATPase function by azoles underlies
synergism with amiodarone
We showed previously that amiodarone triggered a cytosolic H+
and Ca2+ surge in the baker’s yeast and that mutants defective in
ion homeostasis were hypersensitive to amiodarone toxicity [15].
Given the pivotal role of the V-ATPase in maintaining
intracellular cation homeostasis, we predicted that ergosterol
depletion by azole treatment would impair V-ATPase function
and exacerbate disruption of cation homeostasis by amiodarone.
We first tested this hypothesis in the S. cerevisiae model. We used
pH sensitive GFP (pHluorin) to monitor changes in cytosolic pH in
wild type, vma2D and erg24D strains upon exposure to amiodarone
[32]. Cytosolic acidification was most pronounced in the vma2D
mutant consistent with a loss in the ability to transport H+ from the
cytosol to the vacuole. Depletion of ergosterol in erg24D mutant or
by fluconazole treatment also exacerbated cytosolic acidification,
relative to wild type, upon amiodarone addition (Fig. 6A). We
have previously demonstrated defective clearance of cytosolic Ca2+
in vma mutants following exposure to amiodarone [15]. We now
show that pretreatment with fluconazole exacerbates the cytosolic
Ca2+ surge elicited by amiodarone, consistent with defective V-
ATPase function (Fig. 6B).
The proton gradient established by the V-ATPase drives
vacuolar sequestration of excessive cytosolic Ca2+ by H+/Ca2+
exchange mechanisms. The importance of the V-ATPase is
demonstrated by the inability of purified vacuolar vesicles to
sequester 45Ca2+ following treatment with the V-ATPase inhibitor
concanamycin A (Figure 6C). As predicted by our hypothesis,
vacuolar vesicles purified from erg24D or fluconazole-treated wild-
type S. cerevisiae both showed similar impairment in their ability to
sequester Ca2+ (Fig. 6C). Likewise, vacuolar vesicles purified from
C. albicans cells treated with fluconazole were also impaired in
sequestering Ca2+ (Fig. 6D). Thus, our observations provide a
mechanistic basis for previous reports of synergism between azoles
and amiodarone against pathogenic fungi in vitro [15].
To investigate the potential clinical application of this
synergism, we studied the effect of combining fluconazole and
amiodarone in a murine candidiasis model. The microbial burden
of Candida albicans in kidneys was assessed 3 days following
intravenous infection of Balb/C mice. AMD treatment doses were
presented at 5.0 and 25 mg/kg, while FLC doses were 0.5 and
1 mg/kg with treatments given once daily for three days after the
first dose. In the absence of amiodarone, there was a significant
dose-dependent effect of FLC on C. albicans (ratio of geometric
means of the cfu count per 1 mg/kg of FLC was 0.5914, p = 0.01).
In the absence of FLC, amiodarone did not confer a significant
antifungal activity at the concentrations tested (ratio of geometric
means of the cfu count per 1 mg/kg of amiodarone was 0.9996,
p = 0.95). Yet in combination with fluconazole, the two doses of
amiodarone significantly reduced C. albicans infection above and
beyond the dose-dependent effect of fluconazole (ratio of
geometric means of CFU with amiodarone versus without, for
the same dose FLC=0.4969, p,0.001) (Fig. 6E). These data
provide proof of principle that combining azole drugs with other
antifungal compounds that disrupt intracellular cation homeostasis
could be a promising therapeutic strategy to treat systemic fungal
infections.
Discussion
In fungal cells, V-ATPase acidifies intracellular compartments
including the vacuole, endosomes, and late-Golgi. Mutants lacking
V-ATPase exhibit characteristic phenotypes of growth sensitivity
to alkaline pH, calcofluor white, Ca2+ and metal ion stress, and are
unable to grow on high concentrations of non-fermentable carbon
sources [25]. We show that mutants defective in ergosterol
biosynthesis exhibit most of these characteristic vma2 phenotypes.
Furthermore, we showed a reduction of vacuolar acidification by
ergosterol depletion, restoration of vacuolar acidity by ergosterol
feeding, and used biochemical assays of H+ pumping with purified
vacuolar vesicles to collectively demonstrate the requirement of
ergosterol for optimal V-ATPase function. This functional link
explains simultaneous identification of multiple ergosterol biosyn-
thesis genes (erg) and V-ATPase subunit genes (vma) in a number of
genome-wide screens, including sensitivity to low Ca2+, alkaline
stress, and acid stress [33–35]. V-ATPase mutants and ergosterol
biosynthesis mutants also share defects in endocytosis [9,36].
Additionally, in pathogenic fungal species, both vma and erg
mutants are avirulent [30,31,37]. Disruption of V-ATPase
function by ergosterol deprivation provides a mechanistic basis
for these similarities.
To investigate the underlying basis for the requirement of
ergosterol in V-ATPase function, we first checked the localization
Table 1. Ergosterol feeding relieves growth inhibition by
fluconazole.
Treatment Ab600
Control 1.0460.01
Control + ergosterol 0.9660.06
5 mg/ml FLC 1.0060.02
5 mg/ml FLC + ergosterol 0.9460.05
25 mg/ml FLC 0.0560.01
25 mg/ml FLC + ergosterol 0.9660.01
100 mg/ml FLC 0.0460.02
100 mg/ml FLC + ergosterol 0.8860.03
WPY361 (upc2-1 mutant) was grown in YPD containing fluconazole (FLC),
ergosterol, or a combination for 30 hours in a 96-well plate at 30uC in
quadruplicate. Average of Absorbance values at 600 nm (Ab600) and standard
deviations are shown. Ergosterol stock (5 mM in Tween:ethanol [1:1]) was
added for a final concentration of 50 mM. Equal volume of Tween:ethanol was
added to samples without ergosterol as control.
doi:10.1371/journal.ppat.1000939.t001
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and abundance of V-ATPase in erg24D. Fluorescent microscopy
and immunoblot analysis ruled out possible mislocalization and
reduced abundance of V-ATPase in erg24D vacuolar membrane.
In yeast, the V-ATPase complex undergoes rapid reversible
dissociation into non-functional V1 and Vo sectors in response to
glucose withdrawal [38]. A study with Baby Hamster Kidney cells
suggested that increasing ratio of Intact V1/Vo along the endocytic
pathway effectively increased acidity along the compartments in
the pathway [39]. Analyses of immunoblot results in this study
show that V1 and Vo domains are still associated, and V1/Vo ratio
remains unchanged upon ergosterol deprivation by treating cells
with fluconazole and treating vacuolar vesicles with MbCD. These
data rule out dissociation of V1 from Vo domain as the cause of
reduced V-ATPase function, and indicate that ergosterol directly
modulates the activity of V-ATPase. Sphingolipid, another major
component of lipid raft, was thought to affect V-ATPase function
by maintaining the structural integrity of V-ATPase because V1
subunits (Vma1p, Vma2p and Vma5p) dissociate from Vo domain
during Ficoll gradient procedure in the sphingolipid mutant sur4D.
In contrast, Vma2p remained associated with Vph1p after Ficoll
gradient procedure in erg24D mutant and after ergosterol
extraction by MbCD in the wild type. Thus, these two key
membrane lipid components play distinct roles in maintaining V-
ATPase function.
The precise molecular basis of V-ATPase regulation by
ergosterol remains to be determined. In mammalian cells, V-
ATPase has been shown to associate with cholesterol-rich
microdomains, with loss of vesicular acidification reported upon
treatment with b-methylcyclodextrin [40]. A number of studies
showed that inhibitors could interact with lipid bilayer and affect
V-ATPase function by restricting its structural flexibility [41,42].
Mechanisms proposed to explain the regulation of Ca2+-ATPase
and Na+,K+-ATPase by membrane lipids include lowering of free
energy of activation and proper packing at protein-protein
interfaces [43,44]. Altered sterol compositions are known to affect
membrane packing and rigidity: fluorescence anisotropy probes
have revealed increased membrane fluidity and permeability upon
fluconazole treatment [45], consistent with alterations in activity of
membrane-localized pumps and transporters, and a critical role
for ion homeostasis mechanisms in drug treated cells. It is also
possible that ergosterol may affect V-ATPase function indirectly
by modulating regulatory interactions with other proteins. The
complex multi-subunit structure of V-ATPase and its intimate
association with sterols and spingolipids indicate that sophisticated
regulatory mechanisms must be in place to ensure proper
assembly, configuration, and communication among these com-
ponents. Ergosterol depletion may affect other membrane
functions besides vacuolar acidification. The plasma membrane
H+-ATPase, Pma1, is a major efflux mechanism for protons, and is
also found associated with ergosterol-rich microdomains [22,23].
However, we found that Pma1-mediated proton pumping function
was not altered in erg24D, in contrast to the pronounced effect seen
on the V-ATPase. This suggests that membrane proteins have
specific lipid requirement for their functions.
While the molecular target of azole drugs, Erg11p, has been
extensively characterized, not much is known about the cellular
basis of fungal growth inhibition. Inhibition of Erg11p by
fluconazole results in accumulation of lanosterol and its derivative
14-methyl-3,6 diol. In azole resistant erg3 mutants, 14-methyl
fecosterol accumulates upon treatment with fluconazole [26,27].
This has led to the notion that toxicity of sterol derivatives such as
14-methyl-3,6 diol mediates the action of fluconazole [45,46]. We
exploited the ability of a recently described upc2-1 mutation that
allows uptake of ergosterol under aerobic conditions to distinguish
between the effects of byproduct accumulation and ergosterol
depletion on cell growth. The ability of exogenous ergosterol to
reverse growth inhibition by fluconazole supports a plausible
alternative hypothesis that antifungal activity of azoles is due to
ergosterol depletion. Although we ruled out a corresponding
decrease in lanosterol and other derivatives in the ergosterol fed
cells, we cannot exclude the possibility that a specific ratio of
ergosterol to other sterols may counter potential toxic effects. This
possibility could be tested by varying ratios of sterols in upc2-1
feeding experiments; however, 14-methyl-3,6 diol is not commer-
cially available and its potential toxicity cannot be directly assessed
at this time. Furthermore, our results warrant more careful
examination of the role of 14-methyl fecosterol in the potential
compensation of ergosterol function in membranes.
Some reports suggest a role for ROS in the toxicity of azoles to
fungal cells [47]. It is worth noting that cellular ROS level in these
studies was measured with the fluorescent dye DCFH-DA (29,79-
dichlorofluorescin-diacetate) which has also been documented to
respond to pH alterations [48]. Given the effect of azole drugs on
pH homeostasis, the role of ROS in azole-induced growth
inhibition may need to be re-evaluated.
The far-reaching effect of V-ATPase is illustrated by diverse
phenotypes exhibited by V-ATPase mutants. By disrupting the
function of V-ATPase through ergosterol deprivation, azole drugs
can affect a wide range of cellular processes, including cation
homeostasis, protein sorting, processing and degradation. Impor-
tantly, V-ATPase function and vacuolar processing of virulence
factors are required for pathogenesis [30,37]. Although we cannot
preclude additional cellular targets of azole toxicity, disruption of
V-ATPase function is sufficient to repress growth and attenuate
fungal virulence and is likely to be a critical mechanism underlying
antifungal activity of azole drugs.
Amiodarone exhibits antimicrobial activity against a wide range
of fungi and protozoa through disruption of H+ and Ca2+
homeostasis [15,16,49]. Additionally, in vitro studies showed azoles
were synergistic with amiodarone against fungal pathogens, e.g. C.
albicans and C. neoformans [15]. Interestingly, amiodarone interacts
with fluconazole synergistically against fluconazole-resistant clin-
ical isolates of A. fumigatus and C. albicans [50,51]. Moreover, the
synergy of amiodarone and posaconazole has been shown on the
protozoan T. cruzi both in vitro and in vivo [49]. Uncovering the
mechanism underlying this synergism may provide insight guiding
the design of more potent antifungal therapy.
Data in this study show that ergosterol is required for the
optimal function of V-ATPase, a central player in maintaining H+
Figure 5. Fluconazole treatment disrupts V-ATPase function. (A) Vacuolar pH of WT (BY4742) cultures treated with fluconazole at specified
concentrations for 6 hours in YPD. (B) Proton pumping rate and ATPase activity of WT (BY4742) cultures treated with or without fluconazole for
6 hours in YPD. Three independent batches of vacuolar vesicles were isolated and used to assay V-ATPase function. Cultures of upc2-1 mutant,
WYP361, were treated with fluconazole (100 mg/ml), ergosterol (50 mM) or their combination at OD 0.1. Growth (C, representative of three
independent experiments) was assessed at 8 hour post-treatment, and vacuolar pH (D) was assessed at 6 hour post-treatment. (E) WT C. albicans cells
(SC5314) were grown in YPD with or without fluconazole for 5 hours. FM4-64 was added to the cultures to stain vacuoles for 30 min. Cells were
chased with fresh YPD with or without fluconazole for 20 min followed by quinacrine addition for another 5 min. Fluorescence microscopic images of
the cells were taken immediately after washing. Means and standard deviations are plotted. p values of two-tailed t-test are shown.
doi:10.1371/journal.ppat.1000939.g005
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and Ca2+ homeostasis. Therefore, depletion of ergosterol would be
expected to exacerbate the disruption of H+ and Ca2+ homeostasis
upon amiodarone treatment. Indeed, upon ergosterol depletion
either by erg mutations or by azole treatment, 45Ca uptake by
purified vacuolar vesicles was reduced while cytosolic H+ and Ca2+
surges increased upon exposure to amiodarone. Thus, we
conclude that disruption of V-ATPase function in maintaining
cation homeostasis by azoles contributes to the synergy between
azoles and amiodarone.
Recently, we demonstrated that a combination of amiodarone
and fluconazole in C. albicans resulted in dampening of the
transcriptional response to either drug alone [52]. This effect could
potentially stunt cellular stress responses occurring downstream of
drug toxicity and thereby contribute to synergistic effects of the
drugs. These data reveal an additional mechanism contributing to
the synergism that is distinct from the ion homeostasis defects
presented here. We and others have argued that non-overlapping
but complementary insights can be obtained from phenotype versus
transcriptional profiling [18]. Thus, genes involved in membrane
integrity and ion homeostasis such as VMA and ERG, determine
phenotype of growth sensitivity to amiodarone. These genes tend to
be constitutively expressed, have a non redundant function and
represent pathways upstream of the transcriptional response. On
the other hand, genes that are differentially regulated in response to
drug appear to play a collective, rather than individual, response to
adaptation to stress. Taken together, these mechanisms contribute
to a more complete picture of the complex cellular response to drug
toxicity. Finally, in this study, we evaluated the clinical potential of
combining fluconazole and amiodarone in treating fungal infections
in a murine Candidiasis model. The synergy demonstrated in this
experiment is proof-of-principle that combining azoles with agents
disruptive to cation homeostasis is a promising approach to better
manage fungal infections.
Materials and Methods
Yeast strains, media, and reagents
S. cerevisiae erg2 and vma2 mutant strains are from MATa
deletion library (Invitrogen, Carlsbad, CA). WPY361 (MATa
upc2-1 ura3-1 his3-11,-15 leu2-3,-112 trp1-1) was kindly provided
by Dr. Will Prinz (NIDDK). Yeast cells were grown in standard
SC (synthetic complete) medium or YPD (yeast extract, peptone
and dextrose) medium at 30uC with shaking at 250 rpm unless
specified otherwise. Media with non-fermentable carbon source
contains 1% Bacto-yeast extract, 2% Bacto-peptone, 3% glycerol
(v/v) plus 2% ethanol (v/v), or 2% sodium lactate. Antibodies
against Vph1p and Vma2p were purchased from Invitrogen
(Carlsbad, CA) or provided by Dr. Patricia Kane (Upstate Medical
University, New York).
Plasmid construction and yeast genetic manipulation
Plasmid pZR4.1 with pHluorin gene under TEF1 promoter was
constructed to measure yeast cytosolic pH. Briefly, TEF1 promoter
sequence was amplified from BY4742 genomic DNA with primers
XbaITEF1 and BamHITEF1, which incorporate restriction sites of
XbaI and BamHI. CYC1 terminator sequence was amplified with
primers BamHICYC1 and EcoRICYC1, which incorporate
restriction sites of EcoRI and BamHI. pHluorin gene sequence
was amplified from pCB190YpHc plasmid with primers Bam-
HIPhluo and BamHIPhluoR, which incorporate BamHI restriction
site. The amplicons were digested with corresponding restriction
enzymes and ligated sequentially with the backbone of pYE-
plac181, resulting in the gene for pHluorin being flanked by TEF1
promoter and CYC1 terminator. pZR4.1 was transformed to yeast
strains to monitor cytosolic pH change upon exposure to
amiodarone.
Wild type (mating type a) Vph1-GFP and Vma5-GFP strains in
which GFP was fused to the C-terminus of the two proteins were
purchased from Invitrogen. The Vph1-GFP and Vma5-GFP
fragments were amplified from these strains with primers Vph1L2
+ Vph1R1, and Vma5L2 + vma5R1, respectively. The amplicons
were transformed to erg24D to replace the endogenous VPH1 and
VMA5 genes by homologous recombination. Primer sequences are
available upon request.
Ergosterol feeding and sterol analysis
Ergosterol (Sigma) was dissolved in Tween 80:ethanol (1:1) as
5 mM stock. Stocks of ergosterol, fluconazole or their combina-
tion were added at the same time to WPY361 cells in YPD. For
growth assay, stationary cultures were grown in 96-well plates for
30 hours at 30uC. For vacuolar pH measurement and sterol
analysis, log phase cells were treated with ergosterol and
fluconazole for 6 hours. Total sterols were extracted from
,56107 log-phase cells after washing twice with water and
analyzed with an Agilent 6850 gas chromatograph with an HP-1
column and FID as described previously [53]. Retention times for
cholesterol, ergosterol and lanosterol were determined using
standards. Cholesterol was added to each sample to normalize
extraction efficiency.
Vacuolar vesicle purification, MbCD treatment and 45Ca
uptake assay
Vacuolar vesicles were prepared as described previously except
that 10% Ficoll, instead of 8% Ficoll, was used in the second
ultracentrifugation step to facilitate purification of vesicles from
erg24D and fluconazole treated cells [54]. For 45Ca uptake assay,
vacuolar vesicles were incubated in reaction buffer containing
5 mM CaCl2 with tracer quantities of
45CaCl2. After 5 min of
incubation, vacuolar vesicles were filtered onto nitrocellulose
membranes. The filters were washed and processed for liquid
scintillation counting. Concanamycin A was added to 0.5 mM to
assess the dependence of 45Ca uptake by vacuolar vesicles. For
MbCD treatment, vacuolar vesicles were incubated with MbCD
or MbCD preloaded with cholesterol (cholesterol to MbCD ratio
1:20 by weight, Sigma, C4951) for 30 min at 4uC with gentle
Figure 6. Synergy between fluconazole and amiodarone. (A) Early log phase cells expressing pHluorin were grown for 6 hours to mid log
phase (OD ,1) in SC minus leucine medium with or without fluconazole. Amiodarone (10 mM) was injected at the arrow. Measurement was done in
triplicate, and the means and standard deviations are plotted [32]. (B) Early log phase WT cells expressing aequorin were grown with or without
fluconazole for 4 hours. Amiodarone (10 mM) was injected at the arrow. Ca2+-dependent Aequorin luminescence was measured in triplicate as
previously described [15]. For 45Ca uptake, early log phase WT cells of S. cerevisiae (C) and C. albicans (D) were grown with or without fluconazole
(20 mg/ml for S. cerevisiae, 1 mg/ml for C. albicans) for 6 hours. Vacuolar vesicles isolated from these cultures were assayed for MgATP-dependent
45CaCl2 uptake as described in Materials and Methods [33]. Concanamycin A was added to assess V-ATPase dependence of CaCl2 uptake. p values of
two-tailed t-test were shown. (E) Mice infected with C. albicans (ATCC 36082) were treated with vehicle, fluconazole, amiodarone, and their
combination intraperitoneally. On day 4 post-infection, mouse kidneys (5 per group) were removed, weighed, homogenized, serially diluted and then
plated onto YPD agar plates containing chloramphenicol and ampicillin. CFU were counted after 48 hours. Means of CFU per gram of kidney under
each treatment and standard errors are plotted.
doi:10.1371/journal.ppat.1000939.g006
Azoles Disrupt Fungal V-ATPase Function
PLoS Pathogens | www.plospathogens.org 10 June 2010 | Volume 6 | Issue 6 | e1000939
shaking. Vesicles were spun down and suspended in buffer C with
proteinase inhibitors (aprotinin 2 mg/ml, leupeptin 1 mg/ml,
pepstatin 1 mg/ml, chymostatin 2 mg/ml) for V-ATPase function
assays and SDS-PAGE [20,54].
V-ATPase function assays
ATP-dependent proton pumping was assayed by monitoring
change of DA490–540 [36]. The initial H
+ pumping rates were
calculated from the absorbance change in the first 60 seconds.
ATPase activity was assessed by an enzyme-coupled assay
monitoring depletion of NADH through oxidation at 340 nm.
ATPase activity was calculated based on the absorbance decrease
between three and six minutes after initiating the reaction.
Concanamycin A was added at a final concentration of 0.1 mM to
assess the specificity of V-ATPase.
Intracellular pH measurement
Cytosolic pH was measured using pHluorin, a pH-sensitive GFP
[32], under TEF1 promoter in plasmid pZR4.1. Early log phase
cells harboring plasmid pZR4.1 were grown for 6 hours to mid log
phase (OD ,1) in SC minus leucine medium with or without
fluconazole. Cells were collected by centrifugation and suspended
in SC to OD 3 in a 96-well plate, with 200 ml culture in each well.
Amiodarone (stock 300 mM in H2O) was injected to give the
specified final concentration. Fluorescence emission at 520 nm
was measured in triplicate with excitation at 485 nm and 410 nm
in a Fluostar Optima plate reader. Cytosolic pH was calculated
based on the ratio of emission at 520 nm excited at 485 nm and
410 nm against a calibration curve covering pH from 4 to 8
established as described previously [32].
Vacuolar pH was measured with BCECF AM, a pH-
sensitive fluorophore that accumulates in the yeast vacuole
[32]. Strains were grown to mid log phase (OD ,1) in SC
medium. Cells were collected by centrifugation and incubated
in SC containing 50 mM BCECF AM for 25 min. The cells
were washed twice, suspended in SC to OD 2 and transferred
to a 96-well plate. Fluorescence emission at 520 nm was
measured in triplicate with excitation at 485 nm and 450 nm
in a Fluostar Optima plate reader. Vacuolar pH was calculated
based on the ratio of emission at 520 nm at dual excitations of
485 nm and 410 nm against a calibration curve covering pH
from 4 to 8.5.
Proton efflux assay
Proton efflux was assayed in wild-type and erg24D cells as
described previously [55]. Briefly, cells were grown to ,OD 1 in
YPD. 1.56108 cells were pelleted by centrifugation and washed
twice with distilled water. The washed cell pellet was resuspended
in distilled water and placed on ice for 2–3 h. Just prior to use, the
cells were centrifuged and resuspended in 3 ml of water. Once a
stable pH base line was established, glucose was added to 2% to
initiate proton efflux.
Staining of C. albicans cells with quinacrine and FM4-64
Log phase cells of C. albicans (SC5314) were diluted to OD 0.025
and grown in YPD with or without fluconazole (1 mg/ml) for
5 hours. FM4-64 was added to 5 mM and the cultures were grown
for another 30 min. Cells were washed twice in YPD, suspended in
YPD with or without fluconazole, and shaken for 20 min.
Quinacrine was then added to 100 mg/ml and the cultures were
shaken for another 5 min. The cells were collected and washed
twice in YPD and examined by fluorescence microscopy
immediately.
Ethics statement
All animal experimentation was conducted following the United
States Public Health Service guidelines for housing and care of
laboratory animals and performed in accordance with Institutional
regulations after pertinent review and approval by the Institutional
Animal Care and Use Committee of the University of Medicine
and Dentistry of New Jersey.
Murine candidiasis model and antifungal assessment
Female BALB/c mice (age, 6 to 8 weeks; weight, 17 to 20 g)
(Charles River Laboratories, Wilmington, MA) were used
throughout the experiments. The mice were housed in micro-
isolator cages with five animals per group and had access to food
and water ad libitum. All animal experiments were conducted in
the PHRI-UMDNJ Research Animal Facility. Disseminated
infection with C. albicans (ATCC 36082) was induced by injection
of 5.06105 blastoconidia (,5 times the median lethal dose) in
0.1 ml of sterile saline via the lateral tail vein of female BALB/c
mice. Therapy was initiated 3 hours after challenge. Mice were
treated with vehicle, Fluconazole (LKT Laboratories Inc., St. Paul,
MN) (0.1 to 60 mg/kg of body weight/dose), Amiodarone (Henry
Schein Animal Health, Melville, NY) (5.0 or 25 mg/kg of body
weight/dose) or Fluconazole (0.1 to 60 mg/kg of body weight/
dose) + Amiodarone (5.0 or 25 mg/kg of body weight/dose)
administered intraperitoneally once a day for a total of 4 days. On
day 4 post-infection, kidneys from euthanized mice (5 per group,
unless specified) were aseptically removed, weighed, and homog-
enized in sterile saline using an IKA Works ULTRA TURRAX
Tube Disperser Workstation (IKA Works Inc., Wilmington, NC).
Serial dilutions of homogenized kidneys were plated onto YPD
agar plates containing chloramphenicol (70 mg/ml) and ampicillin
(50mg/ml) to eliminate bacterial cross-contamination. Culture
plates were incubated at 30uC for 48 h, after which the CFU were
counted and the number of CFU per gram of tissue was
calculated. The method was sensitive for detection of $10
CFU/g. The culture-negative plates were counted as having 0
CFU/g.
Statistics
The association of C. albicans proliferation with treatment group
was assessed using multiple linear regression of log-transformed
CFU counts. Preliminary model fit analysis was conducted to
confirm that a parsimonious model which included dose-response
slopes for AMD and FLZ, and a term for synergistic effect of dual
drug treatment fit the data as well as the saturated model, where
each of the nine treatment and dosage combinations were
independent predictors (likelihood ratio test p = 0.47). The
regression coefficients for drug dose are interpreted as slopes of
the dose response curves. For the synergistic term, the exponen-
tiated coefficient is the ratio of geometric means of the CFU for
any given dose of each drug when the other drug is present versus
when the other drug is absent. The significance of the association
of CFU with predictors was assessed using Wald t-statistics for the
regression coefficients.
Supporting Information
Figure S1 Sterol profiles of upc2-1 cells treated with fluconazole
and ergosterol. Total sterol from control WYP361 (upc2-1) cells
(A), cells treated with fluconazole (100 mg/ml) for 6 hours (B), and
those treated with fluconazole (100 mg/ml) and ergosterol (50 mM)
together for 6 hours (C) was extracted and analyzed by gas
chromatography. Cholesterol was added to the samples to
normalize extraction efficiency. Ergosterol and lanosterol were
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identified with standards. A major sterol derivative, likely 14-
methyl 3,6-diol, is marked with an asterisk. Analysis was done in
triplicates for each treatment and a representative chromatogram
is shown. (D) Quantification of ergosterol, lanosterol and the major
sterol derivative. Averages of relative amounts and standard
deviations were calculated from triplicate samples and plotted.
Found at: doi:10.1371/journal.ppat.1000939.s001 (0.86 MB TIF)
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